In both the DISCOVER-1 and DISCOVER-2 trials, the researchers assessed guselkumab treatment in biologic-naive patients with active psoriatic arthritis.
Researchers compared the effectiveness of tumor necrosis factor inhibitor combination therapy vs monotherapy in psoriatic arthritis.
Researchers identified physical activity barriers and facilitators among patients with scleroderma.
Researchers determined whether a modified disease activity score (DAS) correlated with the validated DAS in patients with juvenile dermatomyositis.
Researchers in the PEXIVAS trial evaluated and challenged the effect of plasma exchange and glucocorticoid use in ANCA-associated vasculitis.
Researchers identified predictors of flares during and after pregnancy in patients with inactive or stable disease activity and characterized and estimated the frequency of postpartum flares.
Researchers aimed to assess the effect of the 2017 American College of
Cardiology/American Heart Association guidelines definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus.
Researchers discussed the use of musculoskeletal ultrasonography in the management of juvenile idiopathic arthritis.
A recent case report examined the adverse effects of alemtuzumab in a patient with relapsing remitting multiple sclerosis.
